Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Oblimersen + Imatinib in Refractory/Relapsed GIST
NCT00091078Phase 2Terminated
- Sponsor
- National Cancer Institute
- Start
- Sep 2005
- Primary completion
- Jul 2006
- Modality
- Small Interfering RNA (siRNA), Modified DNA Oligonucleotides, Single-strand DNA
- Countries
- 1
01
Overview
A Phase 2 trial of oblimersen in gastrointestinal stromal tumor (GIST), sponsored by National Cancer Institute. Started Sep 2005; status: terminated.
02
Drugs
oblimersen
03
Conditions
gastrointestinal stromal tumor (GIST)
Beyond the preview
Go deeper on NCT00091078.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT00091078.